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In a previous era pneumonia was the scourge of middle age in developed countries and many young people died of this dread disease. In the near past pneumonia and other infectious diseases were considered less important because a miracle antibiotic was available to cure them at the first-sniffle stage of the disease.
Unfortunately, the antibiotics were too good. Humans did not use them with discipline and they were spread around too widely and for too many uses, such as keeping cattle healthier during growth. Individuals with compromised immunity-such as organ transplant patients and AIDS sufferers-were also good incubators for drug-resistant strains. As a result the flexible bacteria modified DNA to produce drug-resistant strains, and now hospital stays pose dangers of infections as well as benefits.
The mechanisms of drug resistance are varied and are discussed in reference to how they occur and how they may be prevented. New enzymes that destroy the antibiotic more effectively can be selected and mutation at binding sites can diminish the effectiveness of the drug, as discussed by Spratt. Davies describes gene modification strategies that bacteria use to develop resistance: "A single base change can render useless a hundred million dollars of pharmaceutical research effort." An indication of strategies to come is the finding that such resistance occurs more often in antibiotics from nature, such as streptomycin, than de novodesigned antibiotics. Nikaido explores decreased drug accessibility to bacterial pathogens that results both from the less permeable membranes that prevent drug action and from the pumps that bacteria use to eliminate drugs. Berkelman, Bryan, Osterholm, LeDuc, and Hughes, in a policy forum, discuss the diminution (because of budget cuts at federal and state levels) of our surveillance system, the national Centers for Disease Control, and the complementary state agencies. Georgopapadakou and Walsh discuss human fungi and their role in infection, an increasingly dangerous area. Gabay describes naturally occurring peptides that exhibit antibacterial or antifungal activity.
News articles by Culotta, Travis, Stone, Nowak, and Kingman illustrate the growing threat and the growing apprehension of drug-resistant strains. The penicillin-resistant pneumococci were found in 50 percent of the cases of pneumonia in Hungarian children and many of the bacteria were also resistant to many other antibiotics that are used as backup medicines. In Europe the spread of drug-resistant tuberculosis strains has been less than in the United States because the tuberculosis surveillance program has been better maintained 
